Skip to main content
Clinical Trials/NCT03149471
NCT03149471
Unknown
N/A

The Role of Endothelial Function Test in Risk Stratification for Early and Late Complications After Pulmonary Embolism

Sheba Medical Center0 sites200 target enrollmentJune 2017

Overview

Phase
N/A
Intervention
Not specified
Conditions
Pulmonary Disease
Sponsor
Sheba Medical Center
Enrollment
200
Primary Endpoint
Post PE complications
Last Updated
8 years ago

Overview

Brief Summary

The aim of this study is to investigate the association between endothelial dysfunction, measured by RHI as assessed by the peripheral arterial tonometry method, and PE complications defined as re-event of PE or DVT, systemic embolism or all-cause mortality

Detailed Description

200 Patients will be identified through routine daily scanning of imaging records (CT, Echocardiography) for patients diagnosed with PE. Presenting signs and symptoms as well as clinical and imaging findings during the initial presentation and hospitalization will be incorporated into a computerized pre-specified electronic CRF. During hospitalization, an endothelial function test will be performed 48 hours post admission. A trained technician will perform the test using the EndoPAT device in order to assess patient RHI, a score less than 1.67 will be considerate as endothelial dysfunction. Patients will then be followed for pre-specified clinical events of up to 1 year post discharge and especially the development of chronic thromboembolic pulmonary disease, post thrombotic syndrome and clinical events. RHI will be assessed during 1-year follow up visit.

Registry
clinicaltrials.gov
Start Date
June 2017
End Date
April 2020
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dr. Shlomi Matetzky

Director , Cardiac Intensive Care Unit

Sheba Medical Center

Eligibility Criteria

Inclusion Criteria

  • Age \>18 years old
  • Patient is hospitalized with the diagnosis of acute PE
  • Clinically stable patients.
  • Clinical diagnosis of PE based on CT scan or nuclear imaging.
  • Willing and able to sign informed consent

Exclusion Criteria

  • Previous myocardial infarction during the last 3 months.
  • Planned surgery or PCI.
  • Inability to perform endothelial function test.
  • Current participation in clinical trial.
  • Substrate or drug abuse or alcohol consumption.

Outcomes

Primary Outcomes

Post PE complications

Time Frame: 2 years

The aim of this study is to investigate the association between endothelial dysfunction, measured by RHI as assessed by the peripheral arterial tonometry method, and PE complications defined as re-event of PE or DVT, systemic embolism or all-cause mortality

Secondary Outcomes

  • HRV(2 years)
  • Biochemistry(2 years)
  • Augmentation Index (AI)(2 years)

Similar Trials